Login to Your Account



Sans Partner, Oxford BioMedica Restarting TroVax Development

By Nuala Moran


Wednesday, March 17, 2010
LONDON - Oxford BioMedica plc is restarting clinical development of its TroVax cancer immunotherapy 12 months after the failure of a Phase III trial in renal cancer led partner Sanofi-Aventis SA to drop the product. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription